Accès ouvert
2023
supplementary-materials
OpenAlex
Ahmed Diab, Michael C. Kao, Keffy Kehrli, Hee Yeon Kim et autres
Materials used in Supplementary Data and additional Methods info
Accès ouvert
2023
supplementary-materials
OpenAlex
Ahmed Diab, Michael C. Kao, Keffy Kehrli, Hee Yeon Kim et autres
Figure S1. Severe DNA replication inhibition in UM-SCC-74a HNSCC line and untransformed primary cells. Figure S2. Efficiency of WEE1 inhibition by AZD1775. Figure S3. Cell cycle progression and ï�§H2AX response in the p53 mutant PCI-15B cells. Figure S4. Inactivation of p53 by …
Accès ouvert
2023
supplementary-materials
OpenAlex
Ahmed Diab, Michael C. Kao, Keffy Kehrli, Hee Yeon Kim et autres
Figure S1. Severe DNA replication inhibition in UM-SCC-74a HNSCC line and untransformed primary cells. Figure S2. Efficiency of WEE1 inhibition by AZD1775. Figure S3. Cell cycle progression and ï�§H2AX response in the p53 mutant PCI-15B cells. Figure S4. Inactivation of p53 by …
Accès ouvert
2023
supplementary-materials
OpenAlex
Ahmed Diab, Michael C. Kao, Keffy Kehrli, Hee Yeon Kim et autres
Materials used in Supplementary Data and additional Methods info
Accès ouvert
2023
other
OpenAlex
Ahmed Diab, Michael C. Kao, Keffy Kehrli, Hee Yeon Kim et autres
Abstract The p53 gene is the most commonly mutated gene in solid tumors, but leveraging p53 status in therapy remains a challenge. Previously, we determined that p53 deficiency sensitizes head and neck cancer cells to AZD1775, a WEE1 kinase inhibitor, and translated …
Accès ouvert
2023
other
OpenAlex
Ahmed Diab, Michael C. Kao, Keffy Kehrli, Hee Yeon Kim et autres
Abstract The p53 gene is the most commonly mutated gene in solid tumors, but leveraging p53 status in therapy remains a challenge. Previously, we determined that p53 deficiency sensitizes head and neck cancer cells to AZD1775, a WEE1 kinase inhibitor, and translated …
Accès ouvert
2023
supplementary-materials
OpenAlex
Russell D. Moser, Chang Xu, Michael C. Kao, James T. Annis et autres
Tables S18-20: Table S18. Secondary validation assay statistical analysis (absolute viability) Table S19. Differential viability and caspase 3/7 dependent apoptosis AUC of secondary validation assay Table S20. Statistical analysis summary differential viability and caspase 3/7 dependent apoptosis
Accès ouvert
2023
supplementary-materials
OpenAlex
Russell D. Moser, Chang Xu, Michael C. Kao, James T. Annis et autres
Tables S9-17: Table S9. HT RNAi primary validation screen with siRNA pool deconvolution Table S10. Differential analysis of primary validation screen (CTG) N=12 Table S11. Differential analysis of primary validation screen (CTG) N=3 Pooled Table S12. Statistical analysis summary of differential viability …
Accès ouvert
2023
supplementary-materials
OpenAlex
Russell D. Moser, Chang Xu, Michael C. Kao, James T. Annis et autres
Tables S1-8:Table S1. Characteristics of the HNSCC cell lines Table S2. Characteristics of the MSCC cell lines with germline mutations in p53 pathway genes Table S3. Human kinome (713 kinases) Sigma Table S4. Murine kinome (572 kinases) Ambion Table S5. Interspecies kinome …
Accès ouvert
2023
supplementary-materials
OpenAlex
Russell D. Moser, Chang Xu, Michael C. Kao, James T. Annis et autres
Supplementary Table Legends
Accès ouvert
2023
supplementary-materials
OpenAlex
Russell D. Moser, Chang Xu, Michael C. Kao, James T. Annis et autres
Figure S2. HFF kinase exclusion plot
Accès ouvert
2023
supplementary-materials
OpenAlex
Russell D. Moser, Chang Xu, Michael C. Kao, James T. Annis et autres
Figure S1. Plate layout for both primary validation screen and secondary assay